Results 71 to 80 of about 33,580 (237)

Eudragit®‐engineered pH‐responsive probiotic microspheres with enhanced gastrointestinal resistance and prolonged storage stability for inflammatory bowel disease therapy

BMEMat, EarlyView.
This study reports the development of AMS@Eud core‐shell microspheres, combining calcium alginate and pH‐responsive Eudragit® L100, which exhibit exceptional gastrointestinal resistance and long‐term storage stability (only 5.28%–9.09% viability loss over 35 days at 4–25°C), and effectively alleviate inflammatory bowel disease via gut microbiota ...
Ming Teng, Xiaomin Luo, Peng Zhang, Chen Yang, Yuniel Ma, Xinhua Liu   +5 more
wiley   +1 more source

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

BMEMat, EarlyView.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie, Jingxing Si, Xiaobei Deng, Jing Tan, Ruijie Zhu, Jizhou Qi, Gaoxia Ma, Bin Wang, Yi Wang, Yunzhou Guo, Yuping Chen, Shiqun Shao, Youqing Shen   +12 more
wiley   +1 more source

Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy

BMEMat, EarlyView.
This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang, Jiawei Cui, Jin Wang, Manfred F. Maitz, Rifang Luo, Yunbing Wang   +5 more
wiley   +1 more source

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

Tailoring drug‐to‐lipid ratio in redox‐responsive lipid‐mimetic prodrug liposomes for superior cabazitaxel delivery and antitumor efficacy

BMEMat, EarlyView.
Redox‐responsive lipid‐mimetic prodrug liposomes with high drug‐to‐lipid ratios enhance cabazitaxel delivery, prolong circulation, and enable tumor‐selective drug release for superior antitumor efficacy and safety. Abstract Liposomes represent one of the most extensively investigated nanocarriers in drug delivery.
Shengyao Xu, Danping Wang, Si Zheng, Zhiyu Kuang, Ya Gao, Haiyu Zhao, Lurong Zhang, Jiayu Guo, Jingyi Zhang, Weiyao Li, Anhua Wang, Hongrui Lei, Zhonggui He, Ken‐ichiro Kamei, Jianzhao Niu, Lingyun Ma, Bingjun Sun   +16 more
wiley   +1 more source

Viscosity of concentrated mRNA solutions: Implications for downstream processing

Biotechnology Progress, EarlyView.
Abstract Messenger RNA (mRNA) therapeutics can be used to protect against infectious disease and for the treatment of cancers and genetic disorders. In order to obtain the desired therapeutic dosage, it is necessary to concentrate the mRNA to levels where the viscosity of the mRNA solutions can become significant.
Amin Javidanbardan, Fatemeh Najafi, Ziqiao Wang, Andrew L. Zydney   +3 more
wiley   +1 more source

Organ-specific immune-mediated reactions to polyethylene glycol and polysorbate excipients: three case reports

Frontiers in Pharmacology
Drug-related acute pancreatitis (AP), acute interstitial nephritis (AIN) and drug-induced liver injury (DILI) are rare but serious adverse drug reactions (ADRs) that can have life-threatening consequences.
Olga Rogozina, Carmen Ruiz-Fernández, Susana Martín-López, Ibtissam Akatbach-Bousaid, Miguel González-Muñoz, Elena Ramírez   +5 more
doaj   +1 more source

Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses

Biotechnology Progress, EarlyView.
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing, Tomoki Igi, Daniel Strauss   +2 more
wiley   +1 more source

Drug‐Coated Balloon‐Based Strategy for De Novo Coronary Artery Disease Across Complex and High‐Risk Indicated Percutaneous Coronary Intervention Risk Categories: A Multicenter Registry Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Evidence regarding the risk‐stratified effectiveness of drug‐coated balloon (DCB)‐based PCI for de novo coronary artery disease (CAD) remains limited, particularly in patients undergoing complex and high‐risk indicated percutaneous coronary intervention (CHIP PCI).
Dong Oh Kang, Sunwon Kim, Ae‐Young Her, Eun‐Seok Shin   +3 more
wiley   +1 more source

DSC, TGA-FTIR and FTIR Assisted by Chemometric Factor Analysis and PXRD in Assessing the Incompatibility of the Antiviral Drug Arbidol Hydrochloride with Pharmaceutical Excipients

Molecules
Arbidol hydrochloride is an antiviral product widely used in Russia and China for the treatment of, among other diseases, influenza. In recent years, it has turned out to be highly effective against COVID-19.
Barbara Rojek, Agata Bartyzel, Wiesław Sawicki, Alina Plenis   +3 more
doaj   +1 more source